Here's What I'm Doing With MOH and CNC Stock...
2 extracted signals · 0 resolved · 2 still active
Deep Value HunterIndependent analyst profile- Source published
- 03 Aug 2026, 15:53 UTC
- Recorded by Tahlil Plus
- 10 Aug 2026, 16:32 UTC
AI-generated source summary
The analysis compares Molina Healthcare (MOH) and Centene Corp (CNC) based on their financial performance and market position within the healthcare insurance sector. While MOH is projected to maintain positive growth with a base case scenario suggesting a 15% IRR and a target value of $244.7, the bear case presents a more challenging outlook with a 0% IRR and $40.5 fair value. The forecast for MOH assumes revenue growth and margin recovery. Centene (CNC), on the other hand, is discussed with a bearish outlook due to declining revenue and margins, leading to a low expected IRR and fair value. The analysis highlights that companies with higher operating margins and more diversified revenue streams, like MOLINA, tend to perform better. The overall outlook for the Medicaid market suggests potential headwinds due to government policy changes and increased competition, but some companies are well-positioned to navigate these challenges.
AI-generated summary based on the source content.
Signal outcomes at a glance
Tracking LiveSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
2 eligible signals linked to this case.
- Source processing completed
Source analysis and structured extraction completed.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- Live evaluation in progress
2 signals remain active.
Deep Value Hunter
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.